Leadership - Allinky Biopharma

ALLINKY Biopharma
Go to content

Molecular science to discover new therapeutic compounds


Patricia Gómez, Ph.D.
  • Partner & Head of Preclinical Research
  • Ph.D. in Organic Chemistry and Molecular Modeling
  • 15 years of experience in drug discovery and development

Asunción Burguete, Ph. D.
  • Head of Business Development
  • Ph.D. in Organic Chemistry
  • 10 years of experience in drug discovery and development

Miguel Vega, MEng & PDD-IESE
  • Partner & Executive in residence
  • 25+ Years of R&D and BD experience: Spanish National Genomic Foundation, UAM, European Commission.
  • Former institutional investor in Sanifit, Genmedica, Bioncotech and VCN Biosciences, among other Spanish biotech start up.

Prof. Juan Gómez-Reino, MD
  • Partner & Clinical Advisor.
  • Former Head of Rheumatology at the University Hospital – Santiago de Compostela.
  • 40+ years of experience in clinical research.
  • Former clinical advisor to top pharmaceutical companies.

Prof. Balbino Alarcón
  • Partner & Scientific Advisor.
  • Full Research Professor at the National Research Council (CSIC) – Madrid.
  • 30+ years of experience in R&D.
  • Scientific advisor to Artax Biopharma.

Prof. Ángel Messeguer
  • Partner & Chemistry Advisor.
  • Full Research Professor at the National Research Council (CSIC) – Barcelona.
  • 40+ years of experience in Medicinal Chemistry.
  • Former scientific advisor to Menarini, Lipotec and Salvat.

Prof. Juan Jesús Pérez
  • Partner & Scientific Advisor.
  • Chair Dept of Chemical Engineering, Polytechnic University of Catalonia – Barcelona.
  • 30+ years of experience in Computational Chemistry.
  • Former scientific advisor to Ferrer.

Prof. Ignacio Torres Alemán
  • Partner & Scientific Advisor.
  • Full Research Professor at the National Research Council (CSIC) - Madrid
  • 30+ years of experience in R&D.
  • Former scientific advisor to Zeltia (Pharmamar).

Diego Labarquilla MEng, MBA-Insead
  • Partner & Investor
  • President of Savera Group.
  • Former corporate investor in Tigenix (acquired by Takeda)
  • Insulin-like growth factor I sensitization rejuvenates sleep patterns in old mice GeroScience (May 2022)
  • A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors Cell Rep. 2022 Mar
  • Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia. Molecular Cancer Feb 2022
  • Discovery of novel 2,3,5-trisubstituted pyridine analogs as potent inhibitors of IL-1β via modulation of the p38 MAPK signaling pathway. Eur J Med Chem. 2021 Nov 5
  • Structure-Activity Studies of Novel di-substituted [1,2,5]oxadiazolo[3,4-b]pyrazine Analogs Targeting the A-loop Regulatory Site of p38 MAP Kinase. Curr Med Chem 2021 Jul 12.
  • Reduced Insulin-Like Growth Factor-I Effects in the Basal Forebrain of Aging Mouse. Front Aging Neurosci. 2021 Sep
  • RRAS2 shapes the TCR repertoire by setting the threshold for negative selection. J Exp Med. 2019 Jul
  • Serum Insulin-Like Growth Factor I Deficiency Associates to Alzheimer's Disease Co-Morbidities. J Alzheimers Dis. 2019 Apr
  • Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation. Neurotherapeutics. 2019 Feb
  • Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. PLoS One. 2019 Feb
  • A window of opportunity for cooperativity in the T Cell Receptor. Nat Commun 2018 Jul
  • R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processes. Sci Signal. 2018 May
  • Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. PLoS One. 2018 May
  • Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018 May
  • Flavonoid allosteric modulation of mutated visual rhodopsin associated with retinitis pigmentosa. Sci Rep. 2017 Sep
  • Insulin Regulates Astrocytic Glucose Handling Through Cooperation With IGF-I. Diabetes. 2017 Jan
  • Astrocytic Insulin Signaling Couples Brain Glucose Uptake with Nutrient Availability. Cell, 2016 Aug
  • A Cholesterol-Based Allostery Model of T Cell Receptor Phosphorylation. Immunity, 2016 May
  • Blockade of the Interaction of Calcineurin with FOXO in Astrocytes Protects Against Amyloid-β-Induced Neuronal Death. J Alzheimers Dis, 2016 Apr
  • Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol Biol Cell, 2008 May
  • Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes. Life Sci, 2007 Oct
Back to content